Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia. / Øen, Silje Kjærnes; Keil, Thomas Morten; Berntsen, Erik Magnus; Aanerud, Joel Fredrik; Schwarzlmüller, Thomas; Ladefoged, Claes Nøhr; Karlberg, Anna Maria; Eikenes, Live.

I: EJNMMI research, Bind 9, Nr. 1, 83, 2019, s. 1-12.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Øen, SK, Keil, TM, Berntsen, EM, Aanerud, JF, Schwarzlmüller, T, Ladefoged, CN, Karlberg, AM & Eikenes, L 2019, 'Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia', EJNMMI research, bind 9, nr. 1, 83, s. 1-12. https://doi.org/10.1186/s13550-019-0553-2

APA

Øen, S. K., Keil, T. M., Berntsen, E. M., Aanerud, J. F., Schwarzlmüller, T., Ladefoged, C. N., Karlberg, A. M., & Eikenes, L. (2019). Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia. EJNMMI research, 9(1), 1-12. [83]. https://doi.org/10.1186/s13550-019-0553-2

CBE

Øen SK, Keil TM, Berntsen EM, Aanerud JF, Schwarzlmüller T, Ladefoged CN, Karlberg AM, Eikenes L. 2019. Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia. EJNMMI research. 9(1):1-12. https://doi.org/10.1186/s13550-019-0553-2

MLA

Vancouver

Author

Øen, Silje Kjærnes ; Keil, Thomas Morten ; Berntsen, Erik Magnus ; Aanerud, Joel Fredrik ; Schwarzlmüller, Thomas ; Ladefoged, Claes Nøhr ; Karlberg, Anna Maria ; Eikenes, Live. / Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia. I: EJNMMI research. 2019 ; Bind 9, Nr. 1. s. 1-12.

Bibtex

@article{fc1cc579ab6c440986f420462756eb56,
title = "Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia",
abstract = "Background: Positron emission tomography/magnetic resonance imaging (PET/MRI) is a promising diagnostic imaging tool for the diagnosis of dementia, as PET can add complementary information to the routine imaging examination with MRI. The purpose of this study was to evaluate the influence of MRI-based attenuation correction (MRAC) on diagnostic assessment of dementia with [18F]FDG PET. Quantitative differences in both [18F]FDG uptake and z-scores were calculated for three clinically available (DixonNoBone, DixonBone, UTE) and two research MRAC methods (UCL, DeepUTE) compared to CT-based AC (CTAC). Furthermore, diagnoses based on visual evaluations were made by three nuclear medicine physicians and one neuroradiologist (PETCT, PETDeepUTE, PETDixonBone, PETUTE, PETCT + MRI, PETDixonBone + MRI). In addition, pons and cerebellum were compared as reference regions for normalization. Results: The mean absolute difference in z-scores were smallest between MRAC and CTAC with cerebellum as reference region: 0.15 ± 0.11 σ (DeepUTE), 0.15 ± 0.12 σ (UCL), 0.23 ± 0.20 σ (DixonBone), 0.32 ± 0.28 σ (DixonNoBone), and 0.54 ± 0.40 σ (UTE). In the visual evaluation, the diagnoses agreed with PETCT in 74% (PETDeepUTE), 67% (PETDixonBone), and 70% (PETUTE) of the patients, while PETCT + MRI agreed with PETDixonBone + MRI in 89% of the patients. Conclusion: The MRAC research methods performed close to that of CTAC in the quantitative evaluation of [18F]FDG uptake and z-scores. Among the clinically implemented MRAC methods, DixonBone should be preferred for diagnostic assessment of dementia with [18F]FDG PET/MRI. However, as artifacts occur in DixonBone attenuation maps, they must be visually inspected to assure proper quantification.",
keywords = "Attenuation correction, PET/MRI, z-scores, dementia",
author = "{\O}en, {Silje Kj{\ae}rnes} and Keil, {Thomas Morten} and Berntsen, {Erik Magnus} and Aanerud, {Joel Fredrik} and Thomas Schwarzlm{\"u}ller and Ladefoged, {Claes N{\o}hr} and Karlberg, {Anna Maria} and Live Eikenes",
year = "2019",
doi = "10.1186/s13550-019-0553-2",
language = "English",
volume = "9",
pages = "1--12",
journal = "EJNMMI Research",
issn = "2191-219X",
publisher = "SpringerOpen",
number = "1",

}

RIS

TY - JOUR

T1 - Quantitative and clinical impact of MRI-based attenuation correction methods in [18F]FDG evaluation of dementia

AU - Øen, Silje Kjærnes

AU - Keil, Thomas Morten

AU - Berntsen, Erik Magnus

AU - Aanerud, Joel Fredrik

AU - Schwarzlmüller, Thomas

AU - Ladefoged, Claes Nøhr

AU - Karlberg, Anna Maria

AU - Eikenes, Live

PY - 2019

Y1 - 2019

N2 - Background: Positron emission tomography/magnetic resonance imaging (PET/MRI) is a promising diagnostic imaging tool for the diagnosis of dementia, as PET can add complementary information to the routine imaging examination with MRI. The purpose of this study was to evaluate the influence of MRI-based attenuation correction (MRAC) on diagnostic assessment of dementia with [18F]FDG PET. Quantitative differences in both [18F]FDG uptake and z-scores were calculated for three clinically available (DixonNoBone, DixonBone, UTE) and two research MRAC methods (UCL, DeepUTE) compared to CT-based AC (CTAC). Furthermore, diagnoses based on visual evaluations were made by three nuclear medicine physicians and one neuroradiologist (PETCT, PETDeepUTE, PETDixonBone, PETUTE, PETCT + MRI, PETDixonBone + MRI). In addition, pons and cerebellum were compared as reference regions for normalization. Results: The mean absolute difference in z-scores were smallest between MRAC and CTAC with cerebellum as reference region: 0.15 ± 0.11 σ (DeepUTE), 0.15 ± 0.12 σ (UCL), 0.23 ± 0.20 σ (DixonBone), 0.32 ± 0.28 σ (DixonNoBone), and 0.54 ± 0.40 σ (UTE). In the visual evaluation, the diagnoses agreed with PETCT in 74% (PETDeepUTE), 67% (PETDixonBone), and 70% (PETUTE) of the patients, while PETCT + MRI agreed with PETDixonBone + MRI in 89% of the patients. Conclusion: The MRAC research methods performed close to that of CTAC in the quantitative evaluation of [18F]FDG uptake and z-scores. Among the clinically implemented MRAC methods, DixonBone should be preferred for diagnostic assessment of dementia with [18F]FDG PET/MRI. However, as artifacts occur in DixonBone attenuation maps, they must be visually inspected to assure proper quantification.

AB - Background: Positron emission tomography/magnetic resonance imaging (PET/MRI) is a promising diagnostic imaging tool for the diagnosis of dementia, as PET can add complementary information to the routine imaging examination with MRI. The purpose of this study was to evaluate the influence of MRI-based attenuation correction (MRAC) on diagnostic assessment of dementia with [18F]FDG PET. Quantitative differences in both [18F]FDG uptake and z-scores were calculated for three clinically available (DixonNoBone, DixonBone, UTE) and two research MRAC methods (UCL, DeepUTE) compared to CT-based AC (CTAC). Furthermore, diagnoses based on visual evaluations were made by three nuclear medicine physicians and one neuroradiologist (PETCT, PETDeepUTE, PETDixonBone, PETUTE, PETCT + MRI, PETDixonBone + MRI). In addition, pons and cerebellum were compared as reference regions for normalization. Results: The mean absolute difference in z-scores were smallest between MRAC and CTAC with cerebellum as reference region: 0.15 ± 0.11 σ (DeepUTE), 0.15 ± 0.12 σ (UCL), 0.23 ± 0.20 σ (DixonBone), 0.32 ± 0.28 σ (DixonNoBone), and 0.54 ± 0.40 σ (UTE). In the visual evaluation, the diagnoses agreed with PETCT in 74% (PETDeepUTE), 67% (PETDixonBone), and 70% (PETUTE) of the patients, while PETCT + MRI agreed with PETDixonBone + MRI in 89% of the patients. Conclusion: The MRAC research methods performed close to that of CTAC in the quantitative evaluation of [18F]FDG uptake and z-scores. Among the clinically implemented MRAC methods, DixonBone should be preferred for diagnostic assessment of dementia with [18F]FDG PET/MRI. However, as artifacts occur in DixonBone attenuation maps, they must be visually inspected to assure proper quantification.

KW - Attenuation correction

KW - PET/MRI

KW - z-scores, dementia

UR - http://www.scopus.com/inward/record.url?scp=85071340294&partnerID=8YFLogxK

U2 - 10.1186/s13550-019-0553-2

DO - 10.1186/s13550-019-0553-2

M3 - Journal article

C2 - 31446507

AN - SCOPUS:85071340294

VL - 9

SP - 1

EP - 12

JO - EJNMMI Research

JF - EJNMMI Research

SN - 2191-219X

IS - 1

M1 - 83

ER -